Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-03-11
2008-03-11
Haddad, Maher M. (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023530
Reexamination Certificate
active
07342106
ABSTRACT:
A substance effective for treating immunopathy where MCP-1 is involved is provided. scFv having a high affinity to human MCP-1 was obtained using phage antibody technique. Based on information of VH chain and VL chain obtained from said scFv, a human anti-human MCP-1 antibody and a human anti-human MCP-1 antibody fragment are obtained. Said antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by MCP-1.
REFERENCES:
patent: 2003/0162737 (2003-08-01), Egashira et al.
patent: 09-67399 (1997-03-01), None
patent: 2000-297098 (2000-10-01), None
patent: WO 01/89582 (2001-11-01), None
patent: WO 02/02640 (2002-01-01), None
patent: WO 02/02640 (2002-01-01), None
Lewin et al. Genes IV. Oxford University Press, p. 810, 1990.
Li et al. Biochemistry 2000. 39:6296-6309.
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 pp. 1979-1983.
Janeway et al. Immunobiology by Current Biology Ltd. 1990. Chapter 3, pp. 3:1-3:38.
Akahoshi, et al, “Expression of monocytes chemotactic and activating factor in rheumatoid arthritis”. Arthritis and Rheumatism. (Jun. 1993). 36(6):762-771.
Boring, et al, “Decreased lesion formation in CCR2 mice reveals a role for chemokinase in the initiation of atherosclerosis”, Nature. (Aug. 27, 1998), 394:894-897.
Gong, et al, “An antagonist of monocytes chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lprmouse model”. J. Exp. Med. (Jul. 7, 1997). 186(1):131-137.
Gosling, et al, “MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B”. Journal of Clinical Investigation. (Mar. 1999). 103(6):773-778.
Grob, et al, “Characterization of a receptor for human monocytes-derived neutrophil chemotactic factor interleukin-8”. Journal of Biological Chemistry. (May 15, 1990). 265(14):8311-8316.
Kaji, et al, “Analysis of peptide motifs recognized with anti-MCP-1 monoclonal antibodies”. Peptide Science. (2000) 33-66.
Kaji, et al, “Peptide mimics of monocytes chemoattractant protein-1 (MCP-1) with an antagonistic activity”. J. Biochem. (2001). 129:577-583.
Koch, et al, “Enhanced production of monocytes chemoattractant protein-1 in rheumatoid arthritis”. Journal of Clinical Investigation. (Sep. 1992). 90:772-229.
Kurihara, et al, “Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor”. J. Exp. Med. (Nov. 17, 1997)., 186(10):1757-1762.
Lei, et al, “Characterization of theErwinia carotovora pelBgene and its product pectate lyase”. Journal of Bacteriology. (Sep. 1987). 169(9):4379-4383.
Marks, et al, “By-passing immunization: human antibodies from V-gene libraries displayed on phage”. J. Mol. Biol. (1991). 222:581-597.
Ogata, et al, “The role of monocytes chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats”. Journal of Pathology. (1997). 182:106-114.
Schrier, et al, “Role of chemokines and cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls”. Journal of Leukocyte Biology. (Mar. 1998). 63:359-363.
Sylvester, et al, “Neutrophil attractant protein=1 and monocytes chemosttractant protein-1 in human serum”. Journal of Immunology. (Sep. 15, 1993). 151(6):3292-3298.
Wada, et al, “Intervention of crescentic glomerulonephritis by antibodies to monocytes chemotactic and activating factor (MCAF/MCP-1)”. FASEB J. (1996). 10:1418-1425.
Yoshimura, et al, “Human monocytes chemoattractant protein-1 (MCP-1): Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE”, FEB Letters. (Feb. 1989). 244(2):487-493.
Yoshimura, et al, “production and characterization of mouse monoclonal antibodies against human monocytes chemoattractant protein=1”. Journal of Immunology. (Oct. 1, 1991). 147(7):2229-2233.
Youssef, et al, “C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis”. Journal of Clinical Investigation. (Aug. 2000). 106(3):361-371.
Nakashima Toshihiro
Nishihara Tsukasa
Sugimura Kazuhisa
Browdy and Neimark PLLC
Crowder Chun
Haddad Maher M.
Judicial Foundation The Chemo-Sero-Therapeutic Research Institut
LandOfFree
Human antihuman MCP-1 antibody and antibody fragment thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human antihuman MCP-1 antibody and antibody fragment thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human antihuman MCP-1 antibody and antibody fragment thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2815503